Abstract
The interactions between a causative agent and a susceptible host involve a series of responses most of which are subclinical or asymptomatic but a few of which are manifested by clinical illness. The factor(s) which tip the balance are poorly understood in both acute and chronic diseases. It is designated here as the clinical illness promoting factor (CIPF), a third ingredient. Among infected persons some leads have been found as to why clinical illness develops: in tuberculosis genetic susceptibility plays a key role, as shown in twin studies; in EBV infections age at the time of infection, genetic, and psychosocial factors determine both the expression and the severity of illness; in poliomyelitis age, exercise in the incubation period, and genetic background are related to the development of paralysis. In the relationship between viruses and cancer, viruses and chronic diseases, or inanimate pathogens like tobacco and lung cancer, we know very little as to the factors that result in clinical disease among the many who are presumably susceptible and fully exposed. Epidemiologic study is urged to identify this CIPF or "third ingredient."
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Evans A. S. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med. 1976 May;49(2):175–195. [PMC free article] [PubMed] [Google Scholar]
- Evans A. S., Comstock G. W. Presence of elevated antibody titres to Epstein-Barr virus before Hodgkin's disease. Lancet. 1981 May 30;1(8231):1183–1186. doi: 10.1016/s0140-6736(81)92351-5. [DOI] [PubMed] [Google Scholar]
- Gutensohn N., Cole P. Epidemiology of hodgkin's disease in the young. Int J Cancer. 1977 May 15;19(5):595–604. doi: 10.1002/ijc.2910190502. [DOI] [PubMed] [Google Scholar]
- Hallee T. J., Evans A. S., Niederman J. C., Brooks C. M., Voegtly j. H. Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J Biol Med. 1974 Sep;47(3):182–195. [PMC free article] [PubMed] [Google Scholar]
- Ho H. C., Kwan H. C., Ng M. H., de The G. Serum IgA antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma. Lancet. 1978 Feb 25;1(8061):436–436. doi: 10.1016/s0140-6736(78)91220-5. [DOI] [PubMed] [Google Scholar]
- Kasl S. V., Evans A. S., Niederman J. C. Psychosocial risk factors in the developmental of infectious mononucleosis. Psychosom Med. 1979 Oct;41(6):445–466. doi: 10.1097/00006842-197910000-00002. [DOI] [PubMed] [Google Scholar]
- Lanier A. P., Henle W., Bender T. R., Henle G., Talbot M. L. Epstein-Barr virus-specific antibody titers in seven Alaskan natives before and after diagnosis of nasopharyngeal carcinoma. Int J Cancer. 1980 Aug;26(2):133–137. doi: 10.1002/ijc.2910260203. [DOI] [PubMed] [Google Scholar]
- Purtilo D. T., DeFlorio D., Jr, Hutt L. M., Bhawan J., Yang J. P., Otto R., Edwards W. Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome. N Engl J Med. 1977 Nov 17;297(20):1077–1080. doi: 10.1056/NEJM197711172972001. [DOI] [PubMed] [Google Scholar]
- WILSON M. G., SCHWEITZER M. Pattern of hereditary susceptibility in rheumatic fever. Circulation. 1954 Nov;10(5):699–704. doi: 10.1161/01.cir.10.5.699. [DOI] [PubMed] [Google Scholar]
- Yi Z., Yuxi L., Chunren L., Sanwen C., Jihneng W., Jisong Z., Huijong Z. Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology. 1980;13(3):162–168. doi: 10.1159/000149121. [DOI] [PubMed] [Google Scholar]
- de-Thé G., Geser A., Day N. E., Tukei P. M., Williams E. H., Beri D. P., Smith P. G., Dean A. G., Bronkamm G. W., Feorino P. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978 Aug 24;274(5673):756–761. doi: 10.1038/274756a0. [DOI] [PubMed] [Google Scholar]